When a trading company or manufacturer places a medicinal product on the market, it first checks, in accordance with the ordinance, whether it is a essential medicinal product.
If so, the company determines whether the medicinal product is subject to a reporting obligation via the Medicines Platform HMP and whether compulsory stockpiling also applies.
Where mandatory stockpiling is required, the company must, in addition to the notification submitted through the Medicines Platform, conclude a mandatory stockpile agreement with the Federal Office for National Economic Supply and notify Helvecura Cooperative.
Based on the monthly sales figures, the required compulsory stock quantity is calculated and a stock build-up plan is agreed with the company subject to compulsory stockpiling.
If no mandatory stockpiling obligation applies, no further action is required within the framework of mandatory stockpiling.